In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis

A. Gramegna, B. C. Millar, F. Blasi, J. S. Elborn, D. G. Downey, J. E. Moore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Pulmonary exacerbations in patients with cystic fibrosis (CF) caused by chronic Gram-negative bacterial infections are associated with reduced survival. These pathogens are usually treated with repeated courses of systemic antimicrobial agents. However, there is associated emergence of multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination that has been demonstrated to have good activity against MDR Pseudomonas aeruginosa. Methods: In this study, C/T was compared with other commonly used intravenous antimicrobial agents against 193 non-fermenting Gram-negative bacteria isolated from CF sputum specimens, including P. aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia and Burkholderia cenocepacia. Minimum inhibitory concentrations (MICs) to C/T were determined by standard Etest assay and were interpreted according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Results: C/T had good in vitro antimicrobial activity against CF clinical isolates of P. aeruginosa in comparison with other antimicrobial agents, with the exception of colistin. C/T also had activity against S. maltophilia but was not active against B. cenocepacia or A. xylosoxidans. Conclusion: C/T showed excellent in vitro activity against P. aeruginosa CF clinical isolates. This antimicrobial agent is a potential therapeutic option when presented with challenging MDR P. aeruginosa and S. maltophilia exacerbations. Further clinical experience and trials in CF are required to determine the place of C/T in clinical practice.

Original languageEnglish
Pages (from-to)224-227
Number of pages4
JournalJournal of Global Antimicrobial Resistance
Volume14
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Gram-Negative Bacteria
Cystic Fibrosis
Pseudomonas aeruginosa
Stenotrophomonas maltophilia
Anti-Infective Agents
Achromobacter denitrificans
Burkholderia cenocepacia
Disk Diffusion Antimicrobial Tests
Gram-Negative Bacterial Infections
Colistin
Microbial Sensitivity Tests
Cephalosporins
In Vitro Techniques
tazobactam drug combination ceftolozane
Sputum
Clinical Trials
Guidelines
Lung
Survival

Keywords

  • Antimicrobial resistance
  • Ceftolozane/tazobactam
  • Cystic fibrosis
  • Pseudomonas aeruginosa
  • Respiratory infection
  • Stenotrophomonas maltophilia

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)

Cite this

In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis. / Gramegna, A.; Millar, B. C.; Blasi, F.; Elborn, J. S.; Downey, D. G.; Moore, J. E.

In: Journal of Global Antimicrobial Resistance, Vol. 14, 01.09.2018, p. 224-227.

Research output: Contribution to journalArticle

@article{ce7b5045a533470aa5a9928cce1f30ec,
title = "In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis",
abstract = "Objectives: Pulmonary exacerbations in patients with cystic fibrosis (CF) caused by chronic Gram-negative bacterial infections are associated with reduced survival. These pathogens are usually treated with repeated courses of systemic antimicrobial agents. However, there is associated emergence of multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination that has been demonstrated to have good activity against MDR Pseudomonas aeruginosa. Methods: In this study, C/T was compared with other commonly used intravenous antimicrobial agents against 193 non-fermenting Gram-negative bacteria isolated from CF sputum specimens, including P. aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia and Burkholderia cenocepacia. Minimum inhibitory concentrations (MICs) to C/T were determined by standard Etest assay and were interpreted according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Results: C/T had good in vitro antimicrobial activity against CF clinical isolates of P. aeruginosa in comparison with other antimicrobial agents, with the exception of colistin. C/T also had activity against S. maltophilia but was not active against B. cenocepacia or A. xylosoxidans. Conclusion: C/T showed excellent in vitro activity against P. aeruginosa CF clinical isolates. This antimicrobial agent is a potential therapeutic option when presented with challenging MDR P. aeruginosa and S. maltophilia exacerbations. Further clinical experience and trials in CF are required to determine the place of C/T in clinical practice.",
keywords = "Antimicrobial resistance, Ceftolozane/tazobactam, Cystic fibrosis, Pseudomonas aeruginosa, Respiratory infection, Stenotrophomonas maltophilia",
author = "A. Gramegna and Millar, {B. C.} and F. Blasi and Elborn, {J. S.} and Downey, {D. G.} and Moore, {J. E.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jgar.2018.03.002",
language = "English",
volume = "14",
pages = "224--227",
journal = "Journal of Global Antimicrobial Resistance",
issn = "2213-7165",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis

AU - Gramegna, A.

AU - Millar, B. C.

AU - Blasi, F.

AU - Elborn, J. S.

AU - Downey, D. G.

AU - Moore, J. E.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objectives: Pulmonary exacerbations in patients with cystic fibrosis (CF) caused by chronic Gram-negative bacterial infections are associated with reduced survival. These pathogens are usually treated with repeated courses of systemic antimicrobial agents. However, there is associated emergence of multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination that has been demonstrated to have good activity against MDR Pseudomonas aeruginosa. Methods: In this study, C/T was compared with other commonly used intravenous antimicrobial agents against 193 non-fermenting Gram-negative bacteria isolated from CF sputum specimens, including P. aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia and Burkholderia cenocepacia. Minimum inhibitory concentrations (MICs) to C/T were determined by standard Etest assay and were interpreted according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Results: C/T had good in vitro antimicrobial activity against CF clinical isolates of P. aeruginosa in comparison with other antimicrobial agents, with the exception of colistin. C/T also had activity against S. maltophilia but was not active against B. cenocepacia or A. xylosoxidans. Conclusion: C/T showed excellent in vitro activity against P. aeruginosa CF clinical isolates. This antimicrobial agent is a potential therapeutic option when presented with challenging MDR P. aeruginosa and S. maltophilia exacerbations. Further clinical experience and trials in CF are required to determine the place of C/T in clinical practice.

AB - Objectives: Pulmonary exacerbations in patients with cystic fibrosis (CF) caused by chronic Gram-negative bacterial infections are associated with reduced survival. These pathogens are usually treated with repeated courses of systemic antimicrobial agents. However, there is associated emergence of multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor combination that has been demonstrated to have good activity against MDR Pseudomonas aeruginosa. Methods: In this study, C/T was compared with other commonly used intravenous antimicrobial agents against 193 non-fermenting Gram-negative bacteria isolated from CF sputum specimens, including P. aeruginosa, Achromobacter xylosoxidans, Stenotrophomonas maltophilia and Burkholderia cenocepacia. Minimum inhibitory concentrations (MICs) to C/T were determined by standard Etest assay and were interpreted according to current European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Results: C/T had good in vitro antimicrobial activity against CF clinical isolates of P. aeruginosa in comparison with other antimicrobial agents, with the exception of colistin. C/T also had activity against S. maltophilia but was not active against B. cenocepacia or A. xylosoxidans. Conclusion: C/T showed excellent in vitro activity against P. aeruginosa CF clinical isolates. This antimicrobial agent is a potential therapeutic option when presented with challenging MDR P. aeruginosa and S. maltophilia exacerbations. Further clinical experience and trials in CF are required to determine the place of C/T in clinical practice.

KW - Antimicrobial resistance

KW - Ceftolozane/tazobactam

KW - Cystic fibrosis

KW - Pseudomonas aeruginosa

KW - Respiratory infection

KW - Stenotrophomonas maltophilia

UR - http://www.scopus.com/inward/record.url?scp=85051147246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051147246&partnerID=8YFLogxK

U2 - 10.1016/j.jgar.2018.03.002

DO - 10.1016/j.jgar.2018.03.002

M3 - Article

AN - SCOPUS:85051147246

VL - 14

SP - 224

EP - 227

JO - Journal of Global Antimicrobial Resistance

JF - Journal of Global Antimicrobial Resistance

SN - 2213-7165

ER -